Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-05 5:01 pm Sale |
2025-03-05 | 13D | Exelixis, Inc. EXEL |
FARALLON CAPITAL PARTNERS LP | 23,439,500 8.400% |
-3,330,000 (-12.44%) |
Filing History |
| 2025-02-18 3:37 pm Purchase |
2025-02-11 | 13G | Aramark ARMK |
FARALLON CAPITAL PARTNERS LP | 13,638,340 5.100% |
2,001,403 (+17.20%) |
Filing History |
| 2025-02-18 3:36 pm Purchase |
2025-02-11 | 13G | The New York Times Company NYT |
FARALLON CAPITAL PARTNERS LP | 9,011,576 5.500% |
1,635,463 (+22.17%) |
Filing History |
| 2025-02-11 5:14 pm Purchase |
2024-12-31 | 13G | Savara Inc. SVRA |
FARALLON CAPITAL PARTNERS LP | 18,288,986 9.990% |
526,453 (+2.96%) |
Filing History |
| 2025-02-11 12:11 pm Purchase |
2024-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA |
FARALLON CAPITAL PARTNERS LP | 2,108,262 9.900% |
83,262 (+4.11%) |
Filing History |
| 2025-02-10 2:33 pm Purchase |
2024-12-31 | 13G | ALEANNA INC ANNA |
FARALLON CAPITAL PARTNERS LP | 1,068,400 2.600% |
1,068,400 (New Position) |
Filing History |
| 2025-02-10 12:47 pm Purchase |
2024-12-31 | 13G | Forte Biosciences, Inc. FBRX |
FARALLON CAPITAL PARTNERS LP | 221,027 3.400% |
69,287 (+45.66%) |
Filing History |
| 2025-02-10 09:00 am Purchase |
2024-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
FARALLON CAPITAL PARTNERS LP | 5,956,488 9.990% |
191,379 (+3.32%) |
Filing History |
| 2025-02-05 7:30 pm Purchase |
2024-12-31 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 8,239,123 9.900% |
31,000 (+0.38%) |
Filing History |
| 2025-02-05 5:23 pm Sale |
2024-12-31 | 13G | The New York Times Company NYT |
FARALLON CAPITAL PARTNERS LP | 7,376,113 4.500% |
-2,100,678 (-22.17%) |
Filing History |
| 2025-02-05 4:28 pm Unchanged |
2024-12-31 | 13G | Elevation Oncology, Inc. ELEV |
FARALLON CAPITAL PARTNERS LP | 3,527,482 6.000% |
0 (Unchanged) |
Filing History |
| 2025-02-05 1:10 pm Purchase |
2024-12-31 | 13G | Perspective Therapeutics, Inc. CATX |
FARALLON CAPITAL PARTNERS LP | 5,316,227 7.600% |
252,000 (+4.98%) |
Filing History |
| 2025-02-04 12:02 pm Purchase |
2024-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
FARALLON CAPITAL PARTNERS LP | 5,674,466 9.900% |
13,600 (+0.24%) |
Filing History |
| 2024-11-14 8:21 pm Purchase |
2024-11-08 | 13G | Perspective Therapeutics, Inc. CATX |
FARALLON CAPITAL PARTNERS LP | 5,064,227 7.300% |
5,064,227 (New Position) |
Filing History |
| 2024-11-08 5:15 pm Purchase |
2024-09-30 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
FARALLON CAPITAL PARTNERS LP | 3,456,063 9.990% |
1,250,073 (+56.67%) |
Filing History |
| 2024-11-08 2:57 pm Sale |
2024-09-30 | 13G | Aramark ARMK |
FARALLON CAPITAL PARTNERS LP | 11,636,937 4.400% |
-5,262,317 (-31.14%) |
Filing History |
| 2024-11-08 2:40 pm Purchase |
2024-09-30 | 13G | Agios Pharmaceuticals, Inc. AGIO |
FARALLON CAPITAL PARTNERS LP | 5,660,866 9.900% |
1,493,264 (+35.83%) |
Filing History |
| 2024-11-08 11:54 am Purchase |
2024-09-30 | 13G | Elevation Oncology, Inc. ELEV |
FARALLON CAPITAL PARTNERS LP | 3,527,482 6.000% |
427,482 (+13.79%) |
Filing History |
| 2024-11-07 09:56 am Purchase |
2024-09-30 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 8,208,123 9.900% |
4,102,370 (+99.92%) |
Filing History |
| 2024-11-06 6:32 pm Purchase |
2024-09-30 | 13G | Savara Inc. SVRA |
FARALLON CAPITAL PARTNERS LP | 17,762,533 9.990% |
3,435,622 (+23.98%) |
Filing History |